Ranbaxy moves into Yemen
Ranbaxy Laboratories, India's largest pharmaceutical company, has launched in Yemen. The New Dehli-based generic giant is operating in the country in partnership with Natco Pharma. The formal opening event was attended by R M Aggarwal, Ambassador of India. Ranbaxy intends to expand into the Yemenese market focusing on the anti-infective, gastrointestinal, cholesterol-lowering and anti-allergic areas. It is the first Indian company to establish a major presence in the Middle East, currently active in 11 countries there. The United Arab Emirates is Ranbaxy's major market in the region where it is the leading generic firm. It is also the first Indian company to be registered in Saudi Arabia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze